KRAS and breast carcinoma: In addition, unlike breast cancer, several aberrations are able to drive trastuzumab resistance in GC, including mutations in EGFR, MET, KRAS, PI3K, and PTEN genes, as well as EGFR, MET, and KRAS amplifications [29].